You just read:

DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH)

News provided by

DURECT Corporation

Mar 27, 2019, 08:00 ET